



**Corporate Update
BIO Investor Forum
San Francisco, CA**

October, 2017

TSX:RVX

This presentation may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this presentation includes forward looking information relating to the Company's clinical trials and the potential role of apabetalone in the treatment of CVD, DM, chronic kidney disease, Orphan diseases, and peripheral artery disease. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this presentation are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.



Corporate Overview

- Resverlogix Corp. (TSX:RVX) is a Calgary and San Francisco based clinical stage biotechnology company focused on the development of **apabetalone**
- Apabetalone (RVX-208) is **a first-in-class** small molecule selective BET bromodomain inhibitor, which acts via an epigenetic mechanism that can turn disease-causing genes off, thereby normalizing gene function
 - Apabetalone is the only selective BET bromodomain inhibitor in clinical trials
- Resverlogix has initiated clinical trials of apabetalone in **three indications**:
 - Cardiovascular Disease (BETonMACE Trial) – Phase 3
 - Chronic Kidney Disease (BETonRENAL Trial) – Phase 2b
 - Fabry's Disease – Phase 2b

Late Stage Trial

RVX is focused on significant unmet need in high-risk CVD, diabetes and CKD patient populations, with a phase 3 trial (BETonMACE) in CVD

Advanced R&D

Resverlogix's in-depth understanding of BET inhibitors and world-class medicinal chemistry allows it to develop candidates with better specificity, which affords the opportunity to target chronic disease through the BET pathway

Market Leader Targeting Unmet Need

Apabetalone is expected to be indicated in several high-risk unmet need patient groups totaling over 10M patients in the top seven markets (US, 5EU and Japan)

Established Safety Profile

Over 1,600 patients have been treated to date with apabetalone with no significant safety issues

Novel Mechanism of Action

Regulation of gene transcription, the turning on or off of various disease-causing genes, unlike the CRISPR approach of changing DNA


Quality Investor Base

Proven track record of attracting high quality and long term institutional investors

Founded	2001
Ticker	TSX: RVX
Market Cap	~C\$180M
Debt	~C\$68.8M
Shares Outstand	112.2M ~132M fully diluted
Cash Burn (Annual)	~C\$40.5M
Finance	\$87M – Announced October 2017

Floating Stock -
~51M Shares

RVX Top Shareholders



- RVX shareholder base consists of several long term investors who have been supportive over 10 years
- RVX maintains a diversified public market float of approximately 51M shares or ~\$85M



DONALD J. MCCAFFREY
President and CEO, Co-Founder

- Co-founder, strategic leader and organizational mentor of the company
- Over 35 years of business experience including 18 years of drug discovery & development
- Personally raised over \$300 million for research and clinical development in the areas of CVD, diabetes, CKD, orphan diseases and other indications of high unmet need



DR. EWELINA KULIKOWSKI, Ph.D
Senior Vice President of Research & Development

- Over 12 years experience in scientific research and drug development
- Involved in the development of apabetalone (RVX-208) from its discovery through to the IND and into clinical development
- Doctorate in Oncology from the University of Calgary in 2004



DR. MICHAEL SWEENEY, MD
Senior Vice President of Clinical Development

- Over 26 years in the pharmaceutical industry
- 11 years at Pfizer Inc
- CMO and VP of Research and Development at Depomed
- VP Medical Affairs at CV Therapeutics, Inc



DR. ELDON R. SMITH, OC, MD,
FRCPC, FCAHS, FAHA, FIACS
Board of Directors Lead Director

- Published more than 250 papers and book chapters
- Former Dean of the Faculty of Medicine at the University of Calgary
- Former Editor-in-Chief of the Canadian Journal of Cardiology
- Past President of the Canadian Cardiovascular Society and the Association of Canadian Medical Colleges, Vice President of the Inter-American Society of Cardiology.

Shenzhen Hepalink Partnership




Resverlogix's partnership with Shenzhen Hepalink represents the largest single molecule deal in the history of China



Resverlogix – Shenzhen Hepalink Exclusive Licensing Agreement

Compound	<ul style="list-style-type: none">• Apabetalone (RVX-208)
Licensor	<ul style="list-style-type: none">• Resverlogix Corp.
Licensee	<ul style="list-style-type: none">• Shenzhen Hepalink Pharmaceutical Co., Ltd.
Territory	<ul style="list-style-type: none">• China, Hong Kong, Taiwan, and Macau
Indications	<ul style="list-style-type: none">• Any approved indication
Deal Structure	<ul style="list-style-type: none">• US\$35M in equity investments in Resverlogix• >US\$400M in projected future China sales milestones and licensing royalties
Developmental Costs	<ul style="list-style-type: none">• Shenzhen Hepalink is responsible for all developmental costs for the licensed territories• This includes the cost of additional clinical trials in the licensed territories, regulatory applications, etc.




Hepalink



Apabetalone and the BET Platform


Differentiation (Advanced Mechanism of Action)



- Resverlogix has discovered compounds that bind the bromodomains of BET proteins with a **high degree of specificity**.
 - Other BET programs hit multiple targets (BRD2, BRD3, BRD4, BRDT, etc.)
 - Our expertise in medicinal chemistry and epigenetics allows us to identify small molecules that target one or a specified subset of BET proteins
 - Resverlogix's apabetalone product candidate specifically targets BRD4
- Our Phase 2 clinical program provided us with **the only blood bank of BET inhibitor-treated patients in the world**
 - In-depth analysis such as proteomics, genomics, and pathway analysis revealed advanced knowledge of BET activities
 - The resulting knowledge from these activities provided a level of sophistication around BET that surpasses that of many others working in this area
- The specificity of Resverlogix's molecules **avoids side effects seen when multiple targets are affected**
 - BET programs in oncology can tolerate a high degree of side effects due to the nature of the disease being treated
 - Chronic conditions such as cardiovascular disease and renal impairment require treatments with a side-effect profile acceptable for long-term treatment

BET Inhibition Impacts the Pathways that Drive Cardiovascular Disease and Kidney Diseases

Apabetalone, a bromodomain extra-terminal (BET) protein inhibitor, inhibits BRD4, thereby regulating the expression of genes and restoring the function of pathways underlying the pathogenesis of CVD and kidney disease




Apabetalone Clinical Trials to Date



Completed Trials

Ongoing Trials








BETonMACE Clinical Program Overview

CVD Program - Phase 2 Data

499 Patients from the ASSURE & SUSTAIN Trials



MACE: Major Adverse Cardiac Events including: death, myocardial infarction, stroke, coronary revascularization, hospitalization for acute coronary syndrome or heart failure

Decrease in MACE was most profound in patients who had a higher level of inflammation, such as patients with diabetes


Note: Patients were censored at 30 days after the last dose of study medication.
Source: ASSURE and SUSTAIN Safety Population. Log-Rank test for between group comparison

CVD Program Moving Forward- BETonMACE CV Outcomes Study



2,400 + subjects

- double blinded
- 1-2 week statin run-in



The study is an event-based trial and continues until 250 narrowly defined MACE events have occurred

Key inclusion criteria

- Type II Diabetes Mellitus
 - HbA1c > 6.5% or history of diabetes medications
- CAD event 7 days - 90 days prior to screening
 - Myocardial infarction (MI), unstable angina or percutaneous coronary intervention
- HDL < 1.04 for males and < 1.17 for females

Prof. Kausik K. Ray

Chair

Imperial College, London

Clinical trial expert

Dr. Henry N. Ginsberg

Member

Columbia University

PI of ACCORD

Dr. Gregory G. Schwartz

Member

VA-Denver

DSMB of RVX phase II trials



Dr. Peter P. Toth

Member

Inflammation expert

Dr. Stephen Nicholls

Member

SAHMRI, Adelaide

PI of RVX phase II trials

Dr. Kamyar Kalantar-Zadeh

Member


UC Irvine

nephrologist and CKD expert

Apabetalone Timeline For CVD Indication



Apabetalone represents a unique opportunity for the expansion into the high vascular risk space and provides potentially unprecedented accretive value






Chronic Kidney Disease Clinical Program Overview

Rationale for Kidney Disease Program

- Apabetalone has demonstrated reductions in alkaline phosphatase (a strong marker of CKD risk) and improvements in eGFR in CKD patients (eGFR < 60 mL/min/1.73m²) with CVD in the phase 2 ASSURE and SUSTAIN trials.




Data Presented in Keynote Address at the 2015 American Society of Nephrology Conference, San Diego

- Resverlogix believes that BET inhibition and apabetalone may have the potential to improve kidney function, as measured by eGFR, in patients suffering from various stages of kidney disease.
- Resverlogix is currently investigating the potential for expansion into specific kidney indications:
 - CKD (Stages 3a and 3b) patients, with a history of CVD (Phase 3 BETonMACE subgroup)
 - High Risk CKD Patients on Dialysis (Phase 2a BETonRenal study)

Kidney Disease: Phase I Study

A Phase I, Open-Label, Parallel Group Study to Evaluate the Safety and Pharmacokinetics of a Single Oral Dose of RVX000222 in Subjects with Severe Renal Impairment



Trial demonstrated that apabetalone has a highly differential effect on protein levels based on disease status, healthy vs sick, reducing a variety of plasma proteins and downregulating pathways activated in the CKD cohort


CKD Program - Phase 1 Data

Effect of Apabetalone on Differentially Expressed Proteins

289 proteins were different between the plasma of CKD patients and matched controls (red indicates higher protein levels in CKD/control)


CKD = Subjects with stage 4 Chronic Kidney Disease

152 of the 289 differentially expressed proteins in the CKD patients were downregulated at 12 hours following one dose of apabetalone



Blue = downregulated;
white = no change;
Red = upregulated

In CKD patients, one dose of apabetalone reduced CKD and CVD biomarkers that were dysregulated at baseline



SOMAscan® Analysis of Plasma Proteome – Phase 1 Trial


Apabetalone Reduces CVD and CKD Biomarkers



	Protein Name	Gene Symbol	Subjects with CKD (stage IV) (n=8) treated with 100 mg Apabetalone		Matched Control Subjects (n=8) treated with 100 mg Apabetalone	
			% Δ from baseline at 12h	p-value	% Δ from baseline at 12h	p-value
Inflammation	Interleukin-6	IL6		0.05	NS	
	Interleukin-1 alpha	IL1A		0.01	NS	
	Interferon gamma	IFNG		0.04	NS	
	TNF receptor superfamily member 1A	TNFRSF1A		0.05	NS	
	C-reactive protein	CRP		0.04	NS	
	Tumor necrosis factor	TNF		0.02	NS	
Cell Adhesion	P-selectin	SELP		0.04	NS	
	E-selectin	SELE		0.01		0.02
	Intercellular adhesion molecule 1	ICAM1		0.05		0.04
	Vascular cell adhesion protein 1	VCAM1		0.01	NS	
Matrix Remodeling Calcification	Fibronectin	FN1		0.02	NS	
	Stromelysin-1	MMP3		0.02	NS	
	Stromelysin-2	MMP10		0.02	NS	
	Osteopontin	SPP1		0.01		0.04
Thrombosis	Plasminogen activator inhibitor 1	SERPINE1		0.04	NS	
	Tissue-type plasminogen activator	PLAT		0.01	NS	
	Urokinase-type plasminogen activator	PLAU		0.01	NS	
	D-dimer	FGA/B/C		0.05	NS	
	Urokinase plasminogen activator surface receptor	PLAUR		0.02	NS	

Apabetalone reduces markers of inflammation, cell adhesion, matrix remodeling, calcification and thrombosis in the CKD cohort after one dose and 12 hours

BETonRENAL Dialysis Study Design



- The study is an sequential cross-over trial to evaluate the safety, tolerability, and efficacy of apabetalone in CKD patients on hemodialysis in addition to standard of care
- 30 CKD patients receiving standard regimens of hemodialysis three days per week
- Clinical sites identified and prepared to begin patient enrollment



Dr. Kamyar Kalantar-Zadeh
Chair
UC Irvine Chief Nephrology



Dr. Marcello Tonelli
Member
University of Calgary Chair Medical Research



Prof. Vincent Brandenburg
Member
University Hospital RWTH Aachen



Dr. Srinivasan Beddhu
Member
University of Utah



Dr. Carmine Zoccali
Member
University Pisa



Dr. Mathias Haarhaus
Member
Karolinska University Hospital

Late Stage Trial

RVX is focused on significant unmet need in high-risk CVD, diabetes and CKD patient populations, with a phase 3 trial (BETonMACE) in CVD

Advanced R&D

Resverlogix's in-depth understanding of BET inhibitors and world-class medicinal chemistry allows it to develop candidates with better specificity, which affords the opportunity to target chronic disease through the BET pathway

Market Leader Targeting Unmet Need

Apabetalone is expected to be indicated in several high-risk unmet need patient groups totaling over 10M patients in the top seven markets (US, 5EU and Japan)

Established Safety Profile

Over 1,600 patients have been treated to date with apabetalone with no significant safety issues

Novel Mechanism of Action

Regulation of gene transcription, the turning on or off of various disease-causing genes, unlike the CRISPR approach of changing DNA

Quality Investor Base

Proven track record of attracting high quality and long term institutional investors